Rby Pharmaceuticals Private Limited - Company Profile

It is a business services private limited company based in Bangalore South, Karnataka, India, established in 2024.
2024 Bangalore South, Karnataka, India Active
Last Updated:
Access Report
About Rby Pharmaceuticals Private Limited

Rby Pharmaceuticals Private Limited, a active private limited company, was established on 13 June 2024 in Bangalore South, Karnataka, India. it holds CIN: U46497KA2024PTC189649. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.

Its leadership includes Vipin Paul (Additional Director), Abinash Pratim Saikia (Director), Rudramuni Basavarajappa (Additional Director). Past directors included Vipin Paul, Swapna Handique. It is based at No. G-1006, Purva Skywood Country Road,, Singasandra,, Bangalore South, Karnataka, 560068.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U46497KA2024PTC189649

  • Registration Number

    189649

  • Incorporation Date

    13 June 2024

  • Authorized Capital

    ₹0.10 M

  • Paid-Up Capital

    ₹0.10 M

  • ROC Code

    Roc Bangalore

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 2 Year, 20 Days
Company report

Rby Pharmaceuticals Private Limited

Company Report FY 2026-2027

Comprehensive Company Insights

Explore comprehensive insights into Rby Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Rby Pharmaceuticals Private Limited?
Current Directors
Name Designation Appointment Date Status
Vipin Paul Additional Director 28 Aug 2024 Current
Abinash Pratim Saikia Director 13 Jun 2024 Current
Rudramuni Basavarajappa Additional Director 28 Jun 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 28 Jun 2025 Past
Pramod Abcsdd Director 28 Aug 2024 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Rby Pharmaceuticals.

Enhance accessibility to Rby Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Rby Pharmaceuticals revenue growth over time
Rby Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Rby Pharmaceuticals?

Unlock access to Rby Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Rby Pharmaceuticals?

Unlock and access historical data on people associated with Rby Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Rby Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rby Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Rby Pharmaceuticals
Recent Activity within the Organization
  • Director Appointment

    The activity Rudramuni Basavarajappa was appointed as a Additional Director was appointed as a Additional Director on 28 Jun 2025 & has been associated with this company since 1 year 5 days . was completed.

  • Director Appointment

    Progress on Vipin Paul was appointed as a Additional Director was appointed as a Additional Director on 28 Aug 2024 & has been associated with this company since 1 year 10 months . was documented.

  • Director Appointment

    Abinash Pratim Saikia was appointed as a Director was appointed as a Director on 13 Jun 2024 & has been associated with this company since 2 years 20 days . was recorded as a recent event.

  • Company Incorporation

    Progress on Rby Pharmaceuticals Private Limited was registered on 13 Jun 2024 with Roc Bangalore & aged 2 years 20 days as per MCA records. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Rby Pharmaceuticals Private Limited?

The CIN of Rby Pharmaceuticals Private Limited is U46497KA2024PTC189649.

Where is Rby Pharmaceuticals Private Limited headquartered?

Rby Pharmaceuticals Private Limited is headquartered at No. G-1006, Purva Skywood Country Road,, Singasandra,, Bangalore South, Karnataka, 560068.

When was Rby Pharmaceuticals Private Limited incorporated?

Rby Pharmaceuticals Private Limited was incorporated on 13 June 2024.

Who are the current directors of Rby Pharmaceuticals Private Limited?

The current directors of Rby Pharmaceuticals Private Limited are

Is Rby Pharmaceuticals Private Limited a listed company?

Rby Pharmaceuticals Private Limited is unlisted.

What is the capital structure of Rby Pharmaceuticals Private Limited?

The authorized capital of Rby Pharmaceuticals Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available